Skip to main content
About the Institute
  • English
  • Français
  • Español
  • Russian

Breadcrumb

  1. Home
  2. Gastroenterology
  3. Rectal cancer: F. nucleatum, a biomarker for relapse?
  • Our publications
    • News
    • Microbiota Mag
    • Thematic pages
    • Experts' point of view
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • Partnerships
    • Press room
    • International Microbiota Observatory
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
    • Xpeer App
  • Useful documents
    • Infographics
    • IBS Diagnosis Check List
    • Patients Stories
    About the Institute

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

Lay public section

Find here your dedicated section
Gastroenterology
Gynecology
Pediatrics
Dermatology

Breadcrumb

  1. Home
  2. Gastroenterology
  3. Rectal cancer: F. nucleatum, a biomarker for relapse?
Gastroenterology

Rectal cancer: F. nucleatum, a biomarker for relapse?

Cancer
Oncology Gastroenterology

In locally advanced rectal cancer, chemotherapy prior to excision usually reduces the abundance of F. nucleatum on the surface of the tumor. However, the relapse rate for the disease may rest on the fate of this bacterium.

Gastroenterology
Gynecology
Pediatrics
Dermatology
  • Our publications
    • News
    • Microbiota Mag
    • Thematic pages
    • Experts' point of view
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • Partnerships
    • Press room
    • International Microbiota Observatory
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
    • Xpeer App
  • Useful documents
    • Infographics
    • IBS Diagnosis Check List
    • Patients Stories
    About the Institute

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

Lay public section

Find here your dedicated section

Sources

This article is based on scientific information

Sharing is caring

Your colleagues might be interested in this topic. Why not share it?

  • Facebook
  • Twitter
  • LinkedIn
  • Mail

About this article

Created 12 November 2020
Updated 04 March 2022

More and more evidence has come to signal Fusobacterium as an important intestinal bacterial pathogen associated with colorectal cancer. However, prior to a recent retrospective study, the bacterium’s role in locally advanced rectal cancer as well as its fate following chemotherapy and its involvement in tumor progression, all remained unknown. This study measured levels of F. nucleatum in the tumor microenvironment of 143 patients prior to the excision of their tumor: 87 of these patients were treated with neoadjuvant radiochemotherapy prior to excision, while the remaining 56 were control subjects.

Lower abundance of F. nucleatum with pre-operative chemotherapy

Visualization and quantification of F. nucleatum using in situ hybridization showed that the bacterium was mainly found on the luminal surface of the tumor and that radiochemotherapy significantly reduced its frequency. The density of F. nucleatum was significantly higher in untreated tumors than in treated tumors (median score of 7.4 versus 1.6), while 58% of tumors tested positive for F. nucleatum in control patients, compared to only 26% in chemotherapy patients.

Abundance is not harmful, but persistence signals relapse

The effects of treatment were evaluated using paired samples (taken before and after radiochemotherapy) from 71 patients. F. nucleatum abundance was not predictive of response to treatment. However, persistence of the bacterium following radiochemotherapy increased the risk of relapse by a factor of nine. Although no causal relationship has been confirmed, this may be due to a lack of immune cytotoxicity activation: tumors that became F. nucleatum-negative following treatment showed a strong increase in CD8+ T cells, whereas tumors that remained F. nucleatum-positive showed no induction of CD8+ T cells in post-treatment samples.

Persistence of F. nucleatum, a future biomarker?

Therefore, the persistence of F. nucleatum following chemotherapy may be associated with high relapse rates in locally advanced rectal cancer, a finding potentially related to the suppression of immune cytotoxicity. This promising biomarker for predicting the risk of relapse following neoadjuvant radiochemotherapy may lead to a more personalized clinical management of rectal cancer.

Sources

Serna G, Ruiz-Pace F, Hernando J, et al. Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer. Ann Oncol. 2020 Oct;31(10):1366-1375.

Tags
Rectal Biomarker Colorectal cancer Chemotherapy Fusobacterium nucleatum CRC

en_view en_sources

    Created 12 November 2020
    Updated 04 March 2022

    About this article

    To know more about this topic.

    Main topic

    Cancer

    Medical practice

    Oncology Gastroenterology

    Content type

    News
    Gastroenterology

    Gut Microbiota #18

    By Pr. Satu PekkalaAcademy of Finland Research Fellow, Faculty of Sport and Health Sciences, University of ...

    Find out more

    Rural environment reduces allergic inflammation by modulating the gut microbiota

    COMMENTED ARTICLE - Children’s section By Pr.Emmanuel Ma...

    Find out more

    A pan-cancer mycobiome analysis reveals fungal involvement in gastrointestinal and lung tumours

    COMMENTED ARTICLE - ADULTS’ SECTION By Pr. Harry SokolGa...

    Find out more

    Covid-19 & the gut microbiota

    OverviewBy Pr. Tao ZuoSYSU Research Institute of Gastroenterology, Guangdong Institute of Gastroenterology,...

    Find out more

    Artificial sweeteners, gut microbiota and metabolic health: an interaction requiring close examination

    By Pr. Karine ClémentSorbonne University, Inserm, Unité d...

    Find out more

    Highlights of Gut Microbiota for Health - World Summit 2023

    By Dr. Nicolas BenechGastroenterology and hepatology, Microbiota Study Group, Hospices Civils de Lyon, Lyon...

    Find out more

    Everything you need to know about Irritable Bowel Syndrome (IBS)

    Accrediting training, infographics, expert’s video, thematic folder, news… Biocodex Microbiota Institute pr...

    Find out more

    Your IBS Diagnosis Check List

    How many patients suffering from gut disorder do you see per week? How many are diagnosed with Irritable Bo...

    Find out more

    Continue reading

    News
    25.10.2022

    Antibiotics: Dr Jekyll and Mr Hyde

    Read the article
    13.09.2023

    Parkinson’s disease: Desulfovibrio bacteria have been found guilty

    Read the article
    18.11.2020

    Gut microbiota signature for cirrhosis

    Read the article
    29.08.2023

    Massive amounts of antibiotic resistance genes found in clouds

    Read the article
    29.08.2023

    Ulcerative colitis: a randomized controlled trial highlights the positive effects of the Mediterranean diet

    Read the article
    Immune checkpoint inhibitor (ICI) efficacy: the right dose of bacteria
    02.06.2022

    Immune checkpoint inhibitor (ICI) efficacy: the right dose of bacteria

    Read the article
    21.03.2022

    Endometriosis and Microbiota: what are the links ?

    Read the article
    Antibiotiques : le mycobiote des nourrissons sous influence
    16.08.2022

    The effect of antibiotics on infant mycobiota

    Read the article
    What's worth reading about microbiota
    Follow us on Twitter
    Read our thematic folder
    The Janus face of Antibiotics: Life Savers & Microbiota Disrupters
    Microbiota 17 EN
    Check out our latest magazine
    The first 1000 days of life
    • Our publications
      • News
      • Microbiota Mag
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
      • International Microbiota Observatory
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographics
      • IBS Diagnosis Check List
      • Patients Stories
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube

    Lay public section

    Find here your dedicated section
    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology
    • English
    • Français
    • Español
    • Russian

    Browse the site

    • Our publications
      • News
      • Microbiota Mag
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
      • International Microbiota Observatory
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographics
      • IBS Diagnosis Check List
      • Patients Stories
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

    Lay public section

    Find here your dedicated section

    Redirection

    You are about to be redirected and leave our website

    • Be redirected
    • Stay on the Biocodex Microbiota Institute's website

    Stay with us !

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    Explore

    13.09.2023

    Parkinson’s disease: Desulfovibrio bacteria have been found guilty

    Read the article
    29.08.2023

    Massive amounts of antibiotic resistance genes found in clouds

    Read the article
    29.08.2023

    Ulcerative colitis: a randomized controlled trial highlights the positive effects of the Mediterranean diet

    Read the article

    Stay updated

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    • Our publications
      • News
      • Microbiota Mag
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
      • International Microbiota Observatory
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographics
      • IBS Diagnosis Check List
      • Patients Stories
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology

    Lay public section

    Find here your dedicated section

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

    © 2022 Biocodex. All rights reserved.

    • Cookies Policy
    • Data protection policy
    • GTU
    • Sitemap
    • Cookies settings
    Biocodex logo